Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: LDL Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery

NCT02891070
View directory record Official record
Conditions
Cerebrospinal Fluid Leak
Interventions
FS VH S/D 500 s-apr, DuraSeal Dural Sealant
Drug · Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Springfield, Illinois • Springfield, Massachusetts • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Early Phase 1 Interventional

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

NCT01980823
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Cancer of Breast
Interventions
Metformin, Atorvastatin, Breast surgery
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT06005597
View directory record Official record
Conditions
Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
Interventions
Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo
Combination Product · Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
45
States / cities
Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

NCT01380730
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Placebo to Evolocumab
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
55
States / cities
Birmingham, Alabama • Tucson, Arizona • Malvern, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

NCT01941836
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Ezetimibe
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
68
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 10, 2026, 2:41 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

NCT00311987
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
3,5-Diiodothyropropionic acid (DITPA) therapy
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Sep 10, 2026, 2:41 PM EDT
Completed No phase listed Observational

Using Nudges to Implement Comparative Effectiveness

NCT01575171
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Nudge
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Obicetrapib in Combination With Ezetimibe

NCT04770389
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions
Obicetrapib 5mg, Ezetimibe 10mg, Placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Lincoln, California • Evanston, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Not applicable Interventional

Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction

NCT02770313
View directory record Official record
Conditions
Intermittent Fasting
Interventions
Intermittent Fasting
Behavioral
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
21 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Chitin-Glucan on Oxidized Low-Density Lipoprotein (LDL)

NCT01232309
View directory record Official record
Conditions
Cardiovascular
Interventions
Chitin-Glucan, Low Dose Chitin-Glucan, Low Dose Chitin-Glucan + Olive Extract, Placebo
Dietary Supplement
Lead sponsor
Stratum Nutrition
Industry
Eligibility
21 Years to 70 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Addison, Illinois • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

NCT02963311
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
ALN-PCSSC, Standard of Care
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
12 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

A Study In Patients With Type 2 Diabetes Mellitus

NCT00256867
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK523338
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
43
States / cities
Tucson, Arizona • Fresno, California • Wheat Ridge, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 10, 2026, 2:41 PM EDT
Active, not recruiting Phase 4 Interventional

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

NCT05850091
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Rosuvastatin, Colchicine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

NCT05694260
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bempedoic acid
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Los Angeles, California • West Covina, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

NCT01763827
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
47
States / cities
Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Not applicable Interventional

Comparison of Outreach Approaches to Increase Enrollment in a Healthy Cholesterol Study

NCT02086539
View directory record Official record
Conditions
Diabetes
Interventions
Large Envelope, Priority Mail, Amazon
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Not applicable Interventional

Miami Healthy Heart Initiative a Behavioral Study on Cardiovascular Risk Factors

NCT01152957
View directory record Official record
Conditions
Diabetes, Heart Disease, Hypertension
Interventions
CARIÑO Project, Enhanced Usual Care
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 3 Interventional

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

NCT00004266
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Lisinopril, Nifedipine, Simvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

NCT03060577
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
Interventions
Inclisiran, Evolocumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL)

NCT00895141
View directory record Official record
Conditions
Dyslipidemia
Interventions
Saturated Fat Diet
Dietary Supplement
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Phytosterols, Ezetimibe, and Cholesterol Metabolism

NCT00863265
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Ezetimibe, Phytosterols + ezetimibe, Placebo
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Impact of Evolocumab in Cardiac Transplant Patients With CAV

NCT03944577
View directory record Official record
Conditions
Heart Transplant
Interventions
Evolocumab
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 10, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SP16 SERPIN-like Peptide Administration in Healthy Individuals

NCT03651089
View directory record Official record
Conditions
Healthy Participants
Interventions
SP16, Placebos
Drug
Lead sponsor
Serpin Pharma, LLC
Other
Eligibility
18 Years to 59 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 10, 2026, 2:41 PM EDT